J. Safra Sarasin Holding AG Has $100.57 Million Stock Position in Gilead Sciences, Inc. $GILD

J. Safra Sarasin Holding AG reduced its position in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 8.7% in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 819,403 shares of the biopharmaceutical company’s stock after selling 78,390 shares during the period. Gilead Sciences accounts for approximately 1.6% of J. Safra Sarasin Holding AG’s holdings, making the stock its 11th biggest position. J. Safra Sarasin Holding AG owned about 0.07% of Gilead Sciences worth $100,574,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also bought and sold shares of the company. Corundum Trust Company INC bought a new position in Gilead Sciences in the 3rd quarter worth $26,000. Howard Hughes Medical Institute bought a new stake in Gilead Sciences during the second quarter valued at about $30,000. MTM Investment Management LLC grew its position in shares of Gilead Sciences by 176.0% in the third quarter. MTM Investment Management LLC now owns 276 shares of the biopharmaceutical company’s stock valued at $31,000 after purchasing an additional 176 shares during the last quarter. Kilter Group LLC acquired a new stake in shares of Gilead Sciences in the second quarter valued at about $33,000. Finally, Millstone Evans Group LLC increased its stake in shares of Gilead Sciences by 58.7% in the third quarter. Millstone Evans Group LLC now owns 319 shares of the biopharmaceutical company’s stock worth $35,000 after purchasing an additional 118 shares during the period. 83.67% of the stock is currently owned by institutional investors and hedge funds.

Insider Transactions at Gilead Sciences

In other Gilead Sciences news, insider Johanna Mercier sold 28,000 shares of the business’s stock in a transaction on Tuesday, February 17th. The shares were sold at an average price of $154.44, for a total value of $4,324,320.00. Following the sale, the insider owned 120,288 shares of the company’s stock, valued at $18,577,278.72. The trade was a 18.88% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Also, Director Jeffrey Bluestone sold 5,000 shares of the stock in a transaction on Tuesday, January 20th. The shares were sold at an average price of $123.50, for a total transaction of $617,500.00. Following the completion of the transaction, the director owned 8,920 shares of the company’s stock, valued at approximately $1,101,620. This represents a 35.92% decrease in their position. The SEC filing for this sale provides additional information. Over the last three months, insiders have sold 299,280 shares of company stock valued at $42,820,550. Company insiders own 0.30% of the company’s stock.

Gilead Sciences Stock Up 1.6%

GILD stock opened at $136.34 on Tuesday. Gilead Sciences, Inc. has a twelve month low of $93.37 and a twelve month high of $157.29. The company has a quick ratio of 1.40, a current ratio of 1.55 and a debt-to-equity ratio of 0.98. The company has a market cap of $169.23 billion, a PE ratio of 20.14, a price-to-earnings-growth ratio of 1.76 and a beta of 0.36. The business’s 50-day simple moving average is $144.32 and its 200 day simple moving average is $128.89.

Gilead Sciences (NASDAQ:GILD) last posted its quarterly earnings results on Tuesday, February 10th. The biopharmaceutical company reported $1.86 EPS for the quarter, beating the consensus estimate of $1.83 by $0.03. Gilead Sciences had a return on equity of 49.46% and a net margin of 28.90%.The firm had revenue of $7.93 billion during the quarter, compared to analysts’ expectations of $7.68 billion. During the same quarter in the prior year, the firm posted $1.90 EPS. The company’s revenue for the quarter was up 4.7% on a year-over-year basis. Gilead Sciences has set its FY 2026 guidance at 8.450-8.850 EPS. On average, research analysts anticipate that Gilead Sciences, Inc. will post 7.95 earnings per share for the current year.

Gilead Sciences Increases Dividend

The company also recently announced a quarterly dividend, which was paid on Monday, March 30th. Investors of record on Friday, March 13th were paid a $0.82 dividend. The ex-dividend date was Friday, March 13th. This is a positive change from Gilead Sciences’s previous quarterly dividend of $0.79. This represents a $3.28 dividend on an annualized basis and a dividend yield of 2.4%. Gilead Sciences’s dividend payout ratio is currently 48.45%.

Wall Street Analyst Weigh In

Several research firms recently weighed in on GILD. Jefferies Financial Group initiated coverage on Gilead Sciences in a research report on Tuesday, March 10th. They set a “buy” rating and a $180.00 price objective for the company. Truist Financial raised their target price on Gilead Sciences from $145.00 to $152.00 and gave the company a “buy” rating in a report on Wednesday, February 11th. Morgan Stanley lifted their price target on Gilead Sciences from $150.00 to $171.00 and gave the stock an “overweight” rating in a research report on Wednesday, February 11th. Deutsche Bank Aktiengesellschaft increased their price objective on Gilead Sciences from $135.00 to $155.00 and gave the company a “buy” rating in a research report on Wednesday, February 11th. Finally, Sanford C. Bernstein restated an “outperform” rating and issued a $160.00 price objective on shares of Gilead Sciences in a research note on Wednesday, February 11th. Twenty-four research analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the company’s stock. According to MarketBeat.com, Gilead Sciences currently has an average rating of “Moderate Buy” and a consensus price target of $157.62.

Gilead Sciences Profile

Gilead Sciences, Inc, founded in 1987 and headquartered in Foster City, California, is a biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of high unmet medical need. The company initially built its reputation in antiviral therapies and has since expanded into oncology, cell therapy and inflammatory diseases. Gilead operates a global research and commercial organization, conducting clinical development and selling medicines in markets around the world.

Gilead’s product portfolio is anchored by antiviral therapies for HIV and viral hepatitis.